AstraZeneca PLC (LON:AZN – Get Free Report) reached a new 52-week high on Monday . The company traded as high as £127.90 ($163.45) and last traded at £127.82 ($163.35), with a volume of 13098839 shares traded. The stock had previously closed at £127 ($162.30).
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on AZN. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a £110 ($140.58) price target on shares of AstraZeneca in a research note on Tuesday, June 18th. Jefferies Financial Group upped their price target on shares of AstraZeneca from GBX 71 ($0.91) to GBX 74 ($0.95) and gave the stock a “hold” rating in a research note on Tuesday, July 2nd. Citigroup reiterated a “buy” rating on shares of AstraZeneca in a report on Tuesday, May 28th. Berenberg Bank reiterated a “buy” rating and issued a £150 ($191.69) price objective on shares of AstraZeneca in a report on Monday, August 5th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a report on Tuesday, June 4th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. According to MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and an average price target of £105.53 ($134.87).
Read Our Latest Research Report on AstraZeneca
AstraZeneca Stock Performance
AstraZeneca Cuts Dividend
The firm also recently declared a dividend, which will be paid on Monday, September 9th. Investors of record on Thursday, August 8th will be paid a dividend of GBX 77.60 ($0.99) per share. This represents a dividend yield of 0.64%. The ex-dividend date is Thursday, August 8th. AstraZeneca’s dividend payout ratio (DPR) is 7,307.69%.
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Read More
- Five stocks we like better than AstraZeneca
- Conference Calls and Individual Investors
- How to Invest in Silver: A Beginner’s Guide
- Consumer Staples Stocks, Explained
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- What Are Dividend Achievers? An Introduction
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.